Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
In 2023 the firm abandoned development of lotiglipron after trial participants showed elevated liver enzymes, and the same year discontinued a twice-daily danuglipron dosing regime after almost three quarters of treated patients experienced nausea, while almost a half developed vomiting and a quarter diarrhoea
Therefore, the potential market size for GLP-1 drugs suggests the broadest possible impacts on private insurance premiums and health system spending
Early Phase 2 data published in the New England Journal of Medicine in 2023 showed considerable promise, but retatrutide has not yet received approval from the MHRA or EMA
More on that packaging in the Medication Handling section
US$ 28.74
US$ 26.92
US$ 23.44
US$ 27.88
US$ 24.41
US$ 22.83
US$ 23.19
US$ 23.10
US$ 22.76
US$ 25.00
